Cambridge Investment Research Advisors
SGTX

Cambridge Investment Research Advisors’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-845
Closed -$16K – 3260
2022
Q1 		$16K Buy
+845
New +$18.8K ﹤0.01% 3128

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cambridge Investment Research Advisors's SGTX Position: Q2 2022 in Review

Cambridge Investment Research Advisors sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2022, closing a stake of 845 shares — an estimated $16K sold.

Cambridge Investment Research Advisors first reported a position in SGTX in Q1 2022 and held it in 1 quarter. The position peaked at $16K in Q1 2022. 37 funds tracked by Wall St. Rank hold SGTX as of Q2 2022.

  • Cambridge Investment Research Advisors reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 845 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $16K.
  • Cambridge Investment Research Advisors first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Sigilon Therapeutics, Inc. Common Stock position peaked at $16K in Q1 2022.
  • 37 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2022, filed 13 Jul 2022.